Immunoprecise Piotroski F Score

IPA -  USA Stock  

USD 4.14  0.15  3.50%

This module uses fundamental data of Immunoprecise Antibodies to approximate its Piotroski F score. Immunoprecise Antibodies F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Immunoprecise Antibodies. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Immunoprecise Antibodies financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Please see Immunoprecise Antibodies Altman Z Score, Immunoprecise Antibodies Correlation, Immunoprecise Antibodies Valuation, as well as analyze Immunoprecise Antibodies Alpha and Beta and Immunoprecise Antibodies Hype Analysis.
  
Refresh
Immunoprecise Antibodies Total Debt is projected to increase significantly based on the last few years of reporting. The past year's Total Debt was at 3.98 Million. The current year Debt Current is expected to grow to about 910.8 K, whereas Debt Non Current is forecasted to decline to about 2.3 M. Immunoprecise Antibodies Current Ratio is projected to increase based on the last few years of reporting. The past year's Current Ratio was at 9.25. The current year Tangible Assets Book Value per Share is expected to grow to 4.00, whereas Book Value per Share is forecasted to decline to 3.25.
At this time, it appears that Immunoprecise Antibodies' Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
1
Current Return On AssetsNegativeFocus
2
Change in Return on AssetsDecreasedFocus
3
Cash Flow Return on AssetsNegativeFocus
4
Current Quality of Earnings (accrual)ImprovingFocus
5
Asset Turnover GrowthIncreaseFocus
6
Current Ratio ChangeIncreaseFocus
7
Long Term Debt Over Assets ChangeHigher LeverageFocus
8
Change In Outstending SharesDecreaseFocus
9
Change in Gross MarginNo ChangeFocus

Immunoprecise Antibodies Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Immunoprecise Antibodies is to make sure Immunoprecise is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Immunoprecise Antibodies' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Immunoprecise Antibodies' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares18.2 M18.9 M
Sufficiently Down
Increasing
Slightly volatile
Weighted Average Shares Diluted18.2 M18.9 M
Sufficiently Down
Increasing
Slightly volatile
Total Assets64.2 M77 M
Fairly Down
Increasing
Slightly volatile
Total Liabilities9.3 MM
Sufficiently Up
Decreasing
Stable
Current Assets60.6 M56.2 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities5.9 M5.5 M
Notably Up
Decreasing
Slightly volatile
Total Debt4.2 MM
Notably Up
Increasing
Slightly volatile
Gross Margin0.720.74
Fairly Down
Increasing
Slightly volatile
Asset Turnover0.360.34
Notably Up
Decreasing
Slightly volatile

Immunoprecise Antibodies F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Immunoprecise Antibodies' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Immunoprecise Antibodies in a much-optimized way.

About Immunoprecise Antibodies Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Weighted Average Shares

18.2 Million

Share
Immunoprecise Antibodies Weighted Average Shares is projected to increase significantly based on the last few years of reporting. The past year's Weighted Average Shares was at 18.95 Million

About Immunoprecise Antibodies Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immunoprecise Antibodies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunoprecise Antibodies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunoprecise Antibodies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunoprecise Antibodies without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunoprecise Antibodies using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Immunoprecise Antibodies Altman Z Score, Immunoprecise Antibodies Correlation, Immunoprecise Antibodies Valuation, as well as analyze Immunoprecise Antibodies Alpha and Beta and Immunoprecise Antibodies Hype Analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
101.5 M
Quarterly Revenue Growth YOY
0.066
Return On Assets
-0.19
Return On Equity
-0.43
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.